Recently, JumpCan Pharmaceutical was honored with the "Golden Information Disclosure Award" in recognition of its outstanding performance in information disclosure, communication methods, public relations management, and investor relations management. The award was announced at the 2024 High-Quality Development Forum for Listed Companies and the 26th Golden Bull Awards Ceremony, hosted by China Securities Journal, where a total of nine awards, including the "Golden Bull Most Valuable Investment Award" and the "Golden Information Disclosure Award" were presented.
The "Golden Information Disclosure Award" focuses on evaluating the quality and efficiency of information disclosure by listed companies. The selection process incorporates multiple dimensions, including financial quality risk screening results, audit opinions on financial reports, the 2023 exchange information disclosure evaluation results, and regulatory inquiry letters, to identify listed companies that excel in information disclosure.
JumpCan Pharmaceutical has consistently adhered to its "Four-One" value philosophy: "To sustain steady growth for the enterprise, to ensure rising income for our employees, to make meaningful tax contributions to the government, and to fulfill our responsibilities with dedication to both society and shareholders." Upholding the principles of true, accurate, complete, timely, and fair information disclosure, the company actively supports multi-channel investor relations management, ensures timely and accurate information disclosure, and holds performance briefings. It promptly responds to investor inquiries on interactive platforms and warmly receives investor research through both online and offline channels. These diversified communication methods enable investors to more conveniently and intuitively understand the company's development progress, fully safeguarding their right to information. JumpCan Pharmaceutical has received an A-grade rating for information disclosure from the Shanghai Stock Exchange for four consecutive years.
In 2023, JumpCan Pharmaceutical won the 25th Golden Information Disclosure Award for Listed Companies. This renewed honor reflects the capital market and investors' full recognition of the company's efforts in information disclosure and investor relations management. Moving forward, the company will continue to enhance its core competitiveness, further improve corporate governance capabilities and operational standards, and deliver long-term stable returns to investors through outstanding performance. Simultaneously, JumpCan Pharmaceutical will fulfill its information disclosure responsibilities with high quality, maintain strong communication with the capital market, create greater value for shareholders and clients, and contribute to the healthy and sustainable development of the industry.